06 April 2020 : Case report
Effect of Pegylated Interferon and Mitomycin C on Ocular Surface Squamous Neoplasia in Xeroderma Pigmentosum: A Case Series
Unusual or unexpected effect of treatment, Rare diseaseQais S. Dirar12ABDEFG*, Hebah M. Musalem1BEF, Selwa A.F. Al-Hazzaa12AG, Abdulaziz A. Al Zoba2BG, Amal A. Almalki12ABDE
Am J Case Rep 2020; 21:e921301
BACKGROUND: Xeroderma pigmentosum (XP) is an autosomal recessive disease caused by mutations in DNA repair genes. Clinical manifestations include extreme sensitivity to ultraviolet (UV) rays, freckle-like pigmentation, ocular abnormalities, and an increased risk of developing neoplasms in sun-exposed areas of the skin, mucous membranes, and eyes. This paper describes the clinical outcome of pegylated interferon alpha 2b (PEG-IFN-α-2b) subconjunctival injections and topical mitomycin C (MMC) in the treatment of ocular surface squamous neoplasia (OSSN) in patients with XP.
CASE REPORT: A series of 3 patients with histopathologically-proven biopsy specimens of XP-associated neoplasia of the eyelids and ocular surface underwent subconjunctival injections of PEG-IFN-α-2 band topical cycles of MMC. There was a noticeable decrease in the size and severity of ocular surface squamous neoplasia, with minimal adverse effects of flu-like symptoms with mild fever and generalized malaise. Transient mental depression was reported in 2 of our patients, and only 1 patient developed autoimmune diabetes mellitus, which required insulin therapy after the discontinuation of the PEG-IFN-α-2b.
CONCLUSIONS: The literature on the specifics of ocular care using PEG-IFN-α-2b for XP-associated OSSN is sparse. However, according to our clinical experience, the combination of PEG-IFN-α-2b subconjunctival injection and the topical cycles of MMC is a promising long-term medical therapy to minimize the development and recurrence of OSSN in XP patients.
Keywords: DNA, Neoplasm, Interferon-alpha, Mitomycin, Xeroderma Pigmentosum, Antibiotics, Antineoplastic, Antiviral Agents, Carcinoma, Squamous Cell, Drug Therapy, Combination, Eye Neoplasms, Interferon alpha-2, Polyethylene Glycols, Recombinant Proteins
30 Sep 2023 : Case reportA 33-Year-Old Man with a 22-Year History of Nephrotic Syndrome Due to Minimal Change Disease Exacerbated Fo...
Am J Case Rep In Press; DOI: 10.12659/AJCR.941621
29 Sep 2023 : Case reportIdiopathic Dilated Cardiomyopathy, Cardiac Failure, and Global Cerebral Atrophy Due to Reduced Cerebral Art...
Am J Case Rep In Press; DOI: 10.12659/AJCR.940892
28 Sep 2023 : Case reportLifetime Follow-Up of a Patient with Metastatic Prostate Cancer Undergoing Multiple Surgical Resections: A ...
Am J Case Rep In Press; DOI: 10.12659/AJCR.941668
Most Viewed Current Articles
06 Dec 2021 : Case reportLipedema Can Be Treated Non-Surgically: A Report of 5 Cases
Am J Case Rep 2021; 22:e934406
07 Dec 2021 : Case reportEdwardsiella tarda: A Classic Presentation of a Rare Fatal Infection, with Possible New Background Risk Fac...
Am J Case Rep 2021; 22:e934347
13 Jul 2022 : Case reportWhistling Scrotum: An Unusual Presentation of Pneumomediastinum in the Setting of an Open Scrotal Wound
Am J Case Rep 2022; 23:e936441